Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07469397
Recruiting Observational

Preliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheath in ICU Patients

NCT07469397 · tracked via the Priya Life Science Taiwan tracker
Sponsor
National Taiwan University Hospital
Phase
Observational
Started
2025-05-15
Last updated
2026-03-13

Condition(s) studied

Removal of Femoral Arterial Sheath in ICU PatientsComplete HemostasisCoronary Artery DiseasePercutaneous Coronary InterventionTranscatheter Aortic Valve Implantation (TAVI)

Investigational drug(s) / intervention(s)

Direct Inspection, medical records browsing

Direct Inspection, medical records browsing: Inspect the puncture site directly and collect data from medical records.

Study summary

Background:Following cardiac catheterization and arterial sheath removal, manual compression is applied until bleeding stops, after which a compression belt is used. Patients must lie supine for at least 6 hours, often experiencing discomfort including back pain, eating difficulties, and urinary problems. The compressed leg is restrained to prevent movement, adding to the discomfort. Despite adhering to this standard procedure, some patients still develop bleeding or hematomas after compression, requiring extended treatment. Current research on predicting compression duration and bleeding risk factors after femoral arterial sheath removal is limited and inconsistent. This study aims to identify factors that can more accurately predict necessary compression time after initial hemostasis, potentially reducing patient discomfort and complications such as prolonged bleeding, extended compression, and hematoma formation, which can impact vital signs.

Purpose:To understand the factors influencing complete hemostasis and supine duration after femoral arterial sheath removal in ICU patients.

Methods:Clinical data were collected through observation, and statistical analysis was performed using SPSS.

Expected Outcomes:To identify factors that influence complete hemostasis and supine duration after femoral arterial sheath removal in ICU patients, and to develop a prediction model that allows clinical units to accurately assess the required supine compression time following femoral arterial sheath removal.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients admitted to the cardiac intensive care unit of this hospital. 2. Patients undergoing femoral arterial sheath removal. 3. Age 20 years or older. Exclusion Criteria: 1. Patients unable to maintain supine position or refusing physical restraints. 2. Patients with severe hematoma, vascular rupture, or other vascular complications present at the femoral arterial puncture site at the time of sheath insertion. 3. Patients with a diagnosis of severe disseminated intravascular coagulation (DIC).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan Recruiting

More National Taiwan University Hospital trials in Taiwan

Improvement of Sleep Disorders in Patients With Alzheimer's Disease After Sunlight Exposure Therapy. Active, not recruiting
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients Starting soon
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection Recruiting
The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCA Recruiting
ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial Recruiting

Other trials for the same condition

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease Recruiting
Randomization of Single vs Multiple Arterial Grafts Recruiting
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease Active, not recruiting
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease Recruiting
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07469397 on ClinicalTrials.gov ↗ ← All trials in Taiwan